Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetNET-2: Lanreotide and Metformin in GI and Lung Carcinoids
NCT02823691Phase 1Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Apr 2016
- Primary completion
- Dec 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanreotide and metformin in gastrointestinal neuroendocrine tumor and Lung Neuroendocrine Tumor, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Status: unknown.
02
Drugs
lanreotidemetformin
03
Conditions
gastrointestinal neuroendocrine tumorLung Neuroendocrine Tumor
Beyond the preview
Go deeper on NCT02823691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823691.